Pizzuti Dana 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Nov 5, 2025
Insider Transaction Report
Form 4
Pizzuti Dana
Chief Med and Dev Officer
Transactions
- Sale
Common Stock
2025-11-03$43.27/sh−100$4,327→ 66,270 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-03−5,000→ 74,042 totalExercise: $16.89Exp: 2032-10-10→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2025-11-03$16.89/sh+5,000$84,450→ 71,270 total - Sale
Common Stock
2025-11-03$42.65/sh−4,900$208,985→ 66,370 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
- [F2]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $42.65 per share. The range of sale prices on the transaction date was $42.14 to $43.09. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
- [F3]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $43.27 per share for 100 shares.
- [F4]The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.